22 May 2013
Keywords: vr776, achieves, clinical, proof, concept, pe, chippenham
Article | 28 May 2007
Chippenham, UK-based Vectura says that data from a Phase IIa proof-of-concept clinical study of VR776, its candidate treatment for
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 May 2007
21 May 2013
© 2013 thepharmaletter.com